Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Phase I, Study in Chinese NSCLC Patients

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

Interventions: Drug: AZD9291 40 mg
Drug: AZD9291 80 mg

First Posted Date: 2015-08-20

Last Posted Date: 2020-02-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 31

Registration Number: NCT02529995

Locations: 🇨🇳
Research Site, Shanghai, China

Study of Tremelimumab in Patients With Advanced Solid Tumors

Phase 2

Completed

Conditions: Pancreatic Ductal Adenocarcinoma
Urothelial Bladder Cancer
Triple-negative Breast Cancer

Interventions: Biological: Tremelimumab monotherapy
Biological: MEDI4736 monotherapy
Biological: MEDI4736 + tremelimumab combination therapy

First Posted Date: 2015-08-19

Last Posted Date: 2023-11-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 64

Registration Number: NCT02527434

Locations: 🇵🇱
Research Site, Łódź, Poland

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3

Active, not recruiting

Conditions: Urothelial Cancer

Interventions: Drug: MEDI4736 (Durvalumab)
Drug: Cisplatin
Drug: Tremelimumab
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2015-08-05

Last Posted Date: 2025-05-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 1126

Registration Number: NCT02516241

Locations: 🇬🇧
Research Site, Wirral, United Kingdom

A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

Phase 1

Completed

Conditions: Tolerability
Safety
Pharmacokinetics
Pharmacodynamics
Healthy Subjects
Rheumatoid Arthritis

Interventions: Drug: AZD9567 Monohydrat
Drug: Placebo oral suspension/ Placebo capsule
Drug: Prednisolone

First Posted Date: 2015-07-31

Last Posted Date: 2018-10-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 72

Registration Number: NCT02512575

Locations: 🇩🇪
Research Site, Berlin, Germany

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Phase 1

Completed

Conditions: Refractory Solid Tumours
Relapsed Small Cell Lung Cancer (SCLC)

Interventions: Drug: AZD1775
Drug: Olaparib

First Posted Date: 2015-07-30

Last Posted Date: 2019-11-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 128

Registration Number: NCT02511795

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Phase 3

Active, not recruiting

Conditions: Stage IB-IIIA Non-small Cell Lung Carcinoma

Interventions: Drug: AZD9291 80 mg/40 mg
Drug: Placebo AZD9291 80 mg/40 mg
Drug: Open-label AZD9291 80 mg/40 mg

First Posted Date: 2015-07-29

Last Posted Date: 2025-05-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 682

Registration Number: NCT02511106

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

A Study of MEDI7352 in Painful Osteoarthritis of the Knee

Phase 1

Completed

Conditions: Chronic Pain

Interventions: Biological: MEDI7352 for IV infusion
Biological: MEDI7352 for Subcutaneous Injection
Biological: Placebo for IV infusion
Biological: Placebo for Subcutaneous Injection

First Posted Date: 2015-07-24

Last Posted Date: 2021-04-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 132

Registration Number: NCT02508155

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population

Completed

Conditions: Ovarian Cancer, Hereditary Ovarian Cancer Syndrome

First Posted Date: 2015-07-21

Last Posted Date: 2023-12-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 276

Registration Number: NCT02503436

Locations: 🇩🇪
Research Site, Wuerzburg, Germany

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Pramlintide acetate
Drug: Lispro insulin U-100
Drug: Regular insulin U-100

First Posted Date: 2015-07-17

Last Posted Date: 2018-11-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 34

Registration Number: NCT02500979

Locations: 🇺🇸
Research Site, Chattanooga, Tennessee, United States

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: AZD9150
Drug: MEDI4736
Drug: AZD5069
Drug: tremelimumab (treme)

First Posted Date: 2015-07-16

Last Posted Date: 2025-04-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 340

Registration Number: NCT02499328

Locations: 🇬🇧
Research Site, Taunton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy